LATITUDE NXT Release 5.0
FDA premarket approval P910077/S156 · decided 2017-04-17
Approval details
- PMA number
- P910077
- Supplement
- S156
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- LATITUDE NXT Release 5.0
- Generic name
- Implantable cardioverter defibrillator (non-CRT)
- Applicant
- Boston Scientific
- Date received
- 2016-10-26
- Decision date
- 2017-04-17
- Days to decision
- 173 days
- Decision code
- APPR
- Product code
- LWS
- Advisory committee
- Cardiovascular
- Expedited review
- No
- Location
- St Paul, MN
- Statement
- Approval for the LATITUDE NXT Patient Management System Release 5.0.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.